SCHEMBL6469274

SCHEMBL6469274

CCCCN(CC)c1cnc(N)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HPGD P15428 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
ALDH1A1 P00352 2/20 0.36
GBA1 P04062 1/20 0.36
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
CRHR1 P34998 6/20 0.34
HTT P42858 2/20 0.33
UTS2R Q9UKP6 1/20 0.33
NCOA1 Q15788 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NCOA3 Q9Y6Q9 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18708818 0.85 GBA1 (0.47) KDM4EALDH1A1GBA1KMT2AMEN1
SCHEMBL5042475 0.81 AR (0.43) MAPTKDM4EALDH1A1GABRPGABRD
SCHEMBL6469271 0.76 SIRT6 (0.41) MAPTKDM4EALDH1A1GBA1KMT2A
SCHEMBL5133492 0.75 AR (0.39) MAPTKDM4EHPGDALDH1A1KMT2A
SCHEMBL5133218 0.72 MAPT (0.35) MAPTKDM4EHPGDNPSR1ALDH1A1
SCHEMBL5134194 0.72 TSHR (0.50) MAPTKDM4EHPGDALDH1A1GBA1
SCHEMBL21769321 0.72 PIK3CD (0.39) GBA1GABRPGABRDGABRA1GABRB1
SCHEMBL5133381 0.71 AR (0.49) MAPTKDM4EHPGDALDH1A1CRHR1
SCHEMBL13447545 0.68 NOS2 (0.47) MAPTKDM4EHPGDALDH1A1KMT2A
SCHEMBL27351970 0.68 CYP2C9 (0.35) CRHR1HTTNCOA1SMN1; SMN2NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA MAPT 19/4885KDM4E 3151/4885HPGD 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.